Dimethyl fumarate

Drug Profile

Dimethyl fumarate

Alternative Names: BG-00012; BG-12; BG-12 oral fumarate; Delayed-release dimethyl fumarate; Delayed-release DMF; FAG-201; Gastro-resistant dimethyl fumarate; Gastro-resistant DMF; Panaclar; Tecfidera

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Phase I Pulmonary arterial hypertension
  • No development reported Rheumatoid arthritis
  • Discontinued Psoriasis

Most Recent Events

  • 17 Jan 2017 Forward Pharma enters into a Settlement and License agreement with Biogen related to oral administration of dimethyl fumarate 480mg for multiple sclerosis (9210362; 9210324)
  • 01 Dec 2016 Biogen completes a phase III trial in Multiple sclerosis in Italy (PO) (NCT02579681)
  • 01 Dec 2016 Phase-I clinical trials in Pulmonary arterial hypertension in USA (PO) (NCT02981082)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top